Chordia Therapeutics Balance Sheet

Financials in millions JPY. Fiscal year is September - August.

Millions JPY. Fiscal year is Sep - Aug.

Fiscal Year	TTM	FY 2024	FY 2023
Period Ending	Feb '25 Feb 28, 2025	Aug '24 Aug 31, 2024	Aug '23 Aug 31, 2023
Cash & Equivalents	3,276	4,330	4,799
Cash & Short-Term Investments	3,276	4,330	4,799
Cash Growth	-	-9.78%	-
Prepaid Expenses	33.53	38.16	52.06
Other Current Assets	117	237.64	40.52
Total Current Assets	3,427	4,605	4,892
Property, Plant & Equipment	2.64	2.75	4.43
Other Intangible Assets	0.17	0.62	2.5
Other Long-Term Assets	22.11	23.59	10.59
Total Assets	3,452	4,632	4,909
Accounts Payable	117.14	382.43	248.43
Accrued Expenses	-	2.3	25.6
Current Income Taxes Payable	27.15	54.29	2.42
Other Current Liabilities	60.69	32.06	131.79
Total Current Liabilities	204.98	471.07	408.24
Other Long-Term Liabilities	0	0	-
Total Liabilities	204.98	471.07	408.24
Common Stock	876.27	845.27	90
Additional Paid-In Capital	9,066	9,035	8,280
Retained Earnings	-6,698	-5,722	-3,895
Comprehensive Income & Other	2.52	2.94	25.93
Shareholders' Equity	3,247	4,161	4,501
Total Liabilities & Equity	3,452	4,632	4,909
Net Cash (Debt)	3,276	4,330	4,799
Net Cash Growth	-	-9.78%	-
Net Cash Per Share	50.70	73.72	85.02
Filing Date Shares Outstanding	68.99	67.68	56.44
Total Common Shares Outstanding	68.99	67.68	56.44
Working Capital	3,222	4,134	4,483
Book Value Per Share	47.06	61.49	79.74
Tangible Book Value	3,246	4,161	4,498
Tangible Book Value Per Share	47.06	61.48	79.70
Machinery	11.88	11.21	10.68

Updated Jan 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.